Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of I.V. Synercid in 75 Pediatric Patients

Status

Terminated

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00240747

Enrollment

Unknown

Registered

2005-10-18

Start date

2000-06-30

Completion date

2005-01-31

Last updated

2012-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gram-Positive Bacterial Infections

Brief summary

Open-label, multicenter, multiple-dose, study of population pharmacokinetics of I.V. Synercid (7.5 mg/kg every 8 hours) in 75 pediatric patients. The purpose is to assess the population pharmacokinetics of Synercid in pediatric patients and to collect additional safety and efficacy data in pediatric patients.

Interventions

DRUGSynercid

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

27 Weeks to 16 Years

Healthy volunteers

Inclusion criteria

* Serious, suspected or documented gram-positive infection

Exclusion criteria

Design outcomes

Primary

Measure	Time frame
Population pharmacokinetics	—

Secondary

Measure	Time frame
Safety	—
Efficacy	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026